Quick-Med Technologies Shows FDA-cleared Nimbus Technology At Prestigious Skin And Wound Care Symposium

Quick-Med will present the poster abstract “New BIOGUARD Antimicrobial Wound Dressing with Advanced NIMBUS Technology.” BIOGUARD™ dressings, which were introduced in June, are the first wound care products to feature the novel, FDA-cleared NIMBUS technology. They serve as a barrier to infection, kill germs absorbed into the dressing, and provide an optimum wound healing environment. End Quote

(1888PressRelease) October 02, 2009 - Gainesville, Florida – Quick-Med Technologies to Present NIMBUS at Prestigious Clinical Symposium on Advances in Skin &Wound Care.

NIMBUS Technology Now Available in BIOGUARD Dressings.

Quick-Med Technologies, Inc. (OTCBB: QMDT) announced today that it will present its unique NIMBUS® technology at the 2009 Clinical Symposium on Advances in Skin and Wound Care. This multidisciplinary meeting of healthcare practitioners is being held in San Antonio, Texas, on October 22-25, 2009.

Quick-Med will present the poster abstract “New BIOGUARD Antimicrobial Wound Dressing with Advanced NIMBUS Technology.” BIOGUARD™ dressings, which were introduced in June, are the first wound care products to feature the novel, FDA-cleared NIMBUS technology. They serve as a barrier to infection, kill germs absorbed into the dressing, and provide an optimum wound healing environment. The NIMBUS active agent stays effective even in the presence of large amounts of proteinaceous exudates. BIOGUARD dressings will not allow a biofilm to form on a freshly debrided or clean wound.

NIMBUS is unique in that it is the only non-leaching antimicrobial dressing; all other antimicrobial dressings rely on the release of toxic chemicals to the wound bed. NIMBUS forms a sterile bacterial barrier that prohibits the transfer of microorganisms into the wound because the microbicidal agent is irreversibly bound to the dressing. NIMBUS is non-toxic, long-lasting and not blocked by organics such as blood, exudates, urine and perspiration.

Quick-Med’s novel NIMBUS antimicrobial technology has been incorporated in BIOGUARD dressings by Derma Sciences, Inc. (OTCBB: DSCI). Product labeling has been allowed by FDA that indicates various organisms such as MRSA, VRE, Pseudomonas aeruginosa and Escherichia coli are killed at levels exceeding 99.999%.

“Traditional wound dressings absorb fluid from the wound and act as a great incubator for bacteria that are shed back into the wound,” said Gregory Schultz, Professor, Institute for Wound Research at the University of Florida and past President of the Wound Healing Society. “This [NIMBUS] is the first bound, antimicrobial material – rather than delivering an antimicrobial into the wound, it creates a barrier that won’t allow bacteria to penetrate the dressing or grow in the wound fluid.”

NIMBUS poses no danger of bacteria developing resistance, or of releasing toxic material into the wound and impeding the wound healing process. It is a novel antimicrobial technology: non-leaching and effective even in high concentrations of body fluids.

BIOGUARD Sales Started in June

NIMBUS barrier gauze is available from Derma Sciences under license from Quick-Med as a sterile barrier for use as a primary dressing for exuding wounds, first and second degree burns and surgical wounds. NIMBUS is marketed under Derma Sciences’ BIOGUARD trademark.

About the Clinical Symposium on Advances in Skin and Wound Care
The 24th Annual Clinical Symposium is a premier educational wound care program within this clinical field and is one of the largest annual gatherings of wound care clinicians in the United States. It has a long, rich history and boasts new content along with the best and brightest speakers from across the country and abroad. The planning panel has developed a unique program with content that is credible, balanced, and relevant to clinical practice.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. For more information, see: www.quickmedtech.com.

CONTACT:
J. Ladd Greeno, CEO
Tel. (888) 835.2211 Ext 102
Email: lgreeno ( @ ) quickmedtech dot com

© 2009 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark of Quick-Med Technologies, Inc. BIOGUARD™ is a trademark of Derma Sciences, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

###

Visit Quick-med Technologies, Inc. Website

space